Guggenheim analyst Christopher Pasquale reiterated a Buy rating on Boston Scientific Corp (NYSE: BSX) yesterday and set a price target of $41. The company’s shares closed yesterday at $33.35.
According to TipRanks.com, Pasquale is a 5-star analyst with an average return of 28.9% and a 83.9% success rate. Pasquale covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Stryker Corporation, and Abiomed.
Boston Scientific Corp has an analyst consensus of Strong Buy, with a price target consensus of $35, a 4.9% upside from current levels. In a report issued on July 5, Needham also reiterated a Buy rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
Boston Scientific Corp’s market cap is currently $46.01B and has a P/E ratio of 476.43. The company has a Price to Book ratio of 6.54.
Based on the recent corporate insider activity of 133 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
